Aadi Bioscience, Inc. (AADI) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Pacific Palisades, CA, アメリカ. 現CEOは David J. Lennon.
AADI を有する IPO日 2018-02-16, 53 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $94.89M.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
